Skip to content
Screener

Bioventus BVS Q2 2026 earnings

Reported August 5, 2026 · Before market open

Revenue$153.2MMiss by $2.2M
EPS$0.22Beat by $0.00
Revenue estimate$155.4M
EPS estimate$0.22
“Bioventus continued its positive momentum in the second quarter, with solid performance that positions us well for continued success in the second half of the year. We remain focused on disciplined execution while continuing to invest in our four growth drivers. We believe this compelling combination will accelerate revenue growth, strengthen profitability and earnings power, and drive significant free cash flow.”
Rob Claypoole

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$149.5M
EPS estimate$0.17

Financials

Q2 2026

Income statement

See full
Revenue$153.2M+3.8%
Gross profit$105.7M+3.5%
Operating income$19.1M+4.1%
Net income$33.4M+348%
EPS (diluted)$0.47+327%

Balance sheet

See full
Cash & equivalents$29.5M-10.5%
Total debt$263.7M-26.9%
Total equity$228.3M+41.6%
Total assets$673.3M-4.7%

Cash flow

See full
Operating cash flow$19.9M-23.4%
CapEx$960.0K+40.6%
Free cash flow$18.9M-25.1%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$901.63M+94.5%
Enterprise value$1.14B+43.5%
P/E16.6×—
P/S1.6×+0.7×

Profitability

See full
Gross margin68.7%+1.1pp
Operating margin10%—
Net margin9.4%+9.2pp
FCF margin16.2%+10.2pp

Returns & leverage

See full
Return on equity28%+27.5pp
Debt / equity1.2×-1.1×
Current ratio1.7×+0.2×

Segments

By product

See full
Pain Treatments$81.7M+11.5%
Surgical Solutions$50.4M-4.5%
Restorative Therapies$21.1M-2.4%

By segment

See full
U.S. Segment$134.5M+4.4%
International Segment$18.7M-0.8%

FAQ

When did Bioventus report Q2 2026 earnings?
Bioventus (BVS) reported Q2 2026 earnings on August 5, 2026 before market open.
What were Bioventus's Q2 2026 revenue and EPS?
Bioventus reported revenue of $153.2M and eps of $0.22 for Q2 2026.
Did Bioventus beat estimates in Q2 2026?
Revenue missed the consensus estimate of $155.4M by $2.2M. EPS beat the consensus estimate of $0.22 by $0.00.
How did Bioventus's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.8% from $147.7M a year earlier and eps grew 4.8% from $0.21.
Where can I find Bioventus's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001665988-26-000041) and the 10-Q periodic report (0001665988-26-000042) directly on SEC EDGAR. The filing index links above go to sec.gov.